Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Dynavax Technologies Corporation (DVAX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: DVAX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $23.27
1 Year Target Price $23.27
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -5.68% | Avg. Invested days 41 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.19B USD | Price to earnings Ratio - | 1Y Target Price 23.27 |
Price to earnings Ratio - | 1Y Target Price 23.27 | ||
Volume (30-day avg) 4 | Beta 1.04 | 52 Weeks Range 9.22 - 14.63 | Updated Date 06/30/2025 |
52 Weeks Range 9.22 - 14.63 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.5 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -20.39% | Operating Margin (TTM) -31.4% |
Management Effectiveness
Return on Assets (TTM) -0.07% | Return on Equity (TTM) -10.45% |
Valuation
Trailing PE - | Forward PE 29.24 | Enterprise Value 813490435 | Price to Sales(TTM) 4.04 |
Enterprise Value 813490435 | Price to Sales(TTM) 4.04 | ||
Enterprise Value to Revenue 2.76 | Enterprise Value to EBITDA 30.92 | Shares Outstanding 120081000 | Shares Floating 101723921 |
Shares Outstanding 120081000 | Shares Floating 101723921 | ||
Percent Insiders 0.58 | Percent Institutions 108.72 |
Analyst Ratings
Rating 2 | Target Price 23.27 | Buy 1 | Strong Buy 2 |
Buy 1 | Strong Buy 2 | ||
Hold - | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Dynavax Technologies Corporation
Company Overview
History and Background
Dynavax Technologies Corporation was founded in 1996. Initially focused on allergy therapies, it evolved to concentrate on vaccines, achieving a major milestone with HEPLISAV-B's approval.
Core Business Areas
- Hepatitis B Vaccines: Development, manufacture, and commercialization of HEPLISAV-B, a hepatitis B vaccine for adults.
- CpG 1018 Adjuvant: Development and potential application of CpG 1018 adjuvant in other vaccines.
Leadership and Structure
Ryan Spencer is the Chief Executive Officer. The organizational structure includes departments for research, development, manufacturing, commercialization, and finance.
Top Products and Market Share
Key Offerings
- HEPLISAV-B: Hepatitis B vaccine for adults, offering higher seroprotection rates and fewer doses than traditional vaccines. Competitors include GSK's Engerix-B and Merck's Recombivax HB. HEPLISAV-B has gained market share in the US adult hepatitis B vaccine market, with sales continuing to increase annually.
Market Dynamics
Industry Overview
The vaccine market is characterized by high barriers to entry, significant regulatory oversight, and a focus on public health. The adult vaccine segment is growing due to aging populations and increasing awareness.
Positioning
Dynavax is positioned as a leader in hepatitis B vaccination with HEPLISAV-B, boasting a novel adjuvant and a strong efficacy profile. It is seeking to leverage its CpG 1018 adjuvant technology for other vaccines.
Total Addressable Market (TAM)
The global hepatitis B vaccine market is projected to reach billions of dollars. Dynavax is focusing on capturing a larger share of the adult market and expanding applications for its adjuvant technology. The global Hepatitis B vaccine market is expected to reach $4.8 Billion in 2024.
Upturn SWOT Analysis
Strengths
- Superior efficacy of HEPLISAV-B
- Novel CpG 1018 adjuvant technology
- Established manufacturing capabilities
- Strong commercialization team
Weaknesses
- Dependence on HEPLISAV-B sales
- Limited pipeline beyond HEPLISAV-B
- Competition from established pharmaceutical companies
- Relatively small market cap compared to peers
Opportunities
- Expansion of HEPLISAV-B into new markets and age groups
- Partnerships to develop vaccines using CpG 1018 adjuvant
- Development of new vaccines targeting unmet medical needs
- Government contracts and stockpiling initiatives
Threats
- Competition from new hepatitis B vaccines
- Adverse events related to HEPLISAV-B
- Regulatory changes impacting vaccine approvals
- Economic downturn affecting vaccine demand
Competitors and Market Share
Key Competitors
- GSK (GSK)
- Merck & Co., Inc. (MRK)
- Emergent BioSolutions Inc. (EBS)
Competitive Landscape
Dynavax has a competitive advantage with HEPLISAV-B's superior efficacy. However, it faces competition from larger pharmaceutical companies with greater resources.
Growth Trajectory and Initiatives
Historical Growth: Dynavax has experienced significant revenue growth since the launch of HEPLISAV-B.
Future Projections: Analysts project continued revenue growth for Dynavax, driven by increasing HEPLISAV-B sales and potential partnerships for CpG 1018 adjuvant. Specific numbers omitted but company data is readily available via SEC filings and financial news sources.
Recent Initiatives: Recent initiatives include expanding the sales force, pursuing new market opportunities for HEPLISAV-B, and seeking partnerships to develop vaccines using CpG 1018 adjuvant.
Summary
Dynavax is a growing biotechnology company with a strong foothold in the hepatitis B vaccine market. HEPLISAV-B's success drives its revenue and profitability. The company needs to diversify its pipeline beyond HEPLISAV-B and mitigate the threat of competition to sustain its growth trajectory. Its adjuvant technology offers significant potential for future partnerships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Dynavax Technologies Corporation Investor Relations
- SEC Filings
- Market Research Reports
- Analyst Estimates
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data is estimated and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Dynavax Technologies Corporation
Exchange NASDAQ | Headquaters EmeryVille, CA, United States | ||
IPO Launch date 2004-02-19 | CEO & Director Mr. Ryan Spencer | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 405 | Website https://www.dynavax.com |
Full time employees 405 | Website https://www.dynavax.com | ||
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also develops rF1V, a plague vaccine candidate in Phase 2 clinical trial; and Z-1018, an investigational vaccine candidate in Phase 1/2 clinical trial for the prevention of shingles in adults aged 50 years and older, as well as HEPLISAV-B for adults on hemodialysis. The company sells its products to hospitals and clinics, integrated delivery networks, public health clinics and prisons, the Department of Defense, the Department of Veterans Affairs, and retail pharmacies through wholesalers and specialty distributors. It has a collaboration agreement with the U.S. Department of Defense; Coalition for Epidemic Preparedness Innovations; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; and Biological E. Limited. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.